Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
President Trump announces multiple judicial nominees, accuses court...
Top House committees accuse Dem fundraising giant of...
Trump to rename Persian Gulf the Arabian Gulf...
‘New sheriff in town’: State finance leader rallies...
Trump announces MAHA advocate Casey Means will be...
Trump offers to help India, Pakistan amid growing...
Lone Republican becomes only lawmaker to vote against...
Trump halts military strikes on Houthis but expert...
Retired judges criticize Trump admin over arrest of...
REAL ID deadline comes and goes – airports...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

by admin September 23, 2024
September 23, 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved the required response rate to support continued enrolment in the study. Six (6) patients have now recorded confirmed partial responses (PRs) out of 16 assessed at the four-month timepoint, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

HIGHLIGHTS

Six (6) patients in the Company’s ACCENT trial in pancreatic cancer have now achieved the required reduction in tumour size with no detection of new lesionsThe ACCENT trial can now proceed to recruit the next cohort of 24 patients, giving a total of 50 patients on studyThe ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients

The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period.

A total of 50 patients are planned for the Phase 2a ACCENT trial. With the six (6) confirmed PRs now obtained, recruitment of the remaining 24 patients in the trial will begin at the existing open trial sites in Australia and South Korea. Recruitment of the second cohort of patients is expected to be completed by end of Q1 2025.

A detailed interim analysis of the Phase 2a trial data obtained to date will be reported in the coming weeks; however, key points are noted below:

Narmafotinib continues to be generally well tolerated by patients with no safety trends identified or dose reductions recorded to dateIn addition to 6 confirmed PRs, there have been 7 patients who have recorded stable disease over 2 or more months, including one patient whose stable disease has improved to achieve a partial response at their 4-month assessment

Amplia CEO and MD Dr Chris Burns commented: “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial’

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Operations Update
next post
Nordic Nickel Limited (ASX: NNL) – Trading Halt

You may also like

CHARBONE Hydrogen Signed a USD 50 Million Construction...

May 2, 2025

Crypto Market Recap: TradFi Deepens Crypto Collaboration, BlackRock...

March 16, 2025

13 Canadian Crypto ETFs in 2025

April 25, 2025

FPX Nickel Provides Update on 2025 Community Initiatives

April 22, 2025

Global Markets See Sharp Declines as US Recession...

August 7, 2024

First Gold Doré Following Successful Carbon Strip

February 5, 2025

What Factors Impact Graphene Cost?

February 11, 2025

Crypto Market Recap: Trump Signs First Crypto Bill,...

April 12, 2025

WESTERN COPPER AND GOLD WELCOMES FEDERAL FUNDING FOR...

September 23, 2024

Element79 Announces Private Placement

October 26, 2024

Recent Posts

  • President Trump announces multiple judicial nominees, accuses court system of blocking him from doing his job
  • Top House committees accuse Dem fundraising giant of facilitating ‘bad actors’ in bombshell DOJ letter
  • Trump to rename Persian Gulf the Arabian Gulf ahead of US-Iran nuclear talks, Middle East trip: report
  • ‘New sheriff in town’: State finance leader rallies around key Trump victory saving ‘taxpayer dollars’
  • Trump announces MAHA advocate Casey Means will be new surgeon general nominee

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (710)
    • Investing (2,051)
    • Politics (2,543)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.